ERAS-801

DRUG2 trials

Sponsors

Katmai Pharmaceuticals Inc., Memorial Sloan Kettering Cancer Center

Conditions

GlioblastomaGlioblastoma MultiformeGliosarcoma

Phase 1

A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)

Active, not recruitingNCT05222802

Katmai Pharmaceuticals Inc.Glioblastoma Multiforme

Start: 2022-02-25End: 2025-09-30Updated: 2025-08-17

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

RecruitingNCT06934889

Memorial Sloan Kettering Cancer CenterGlioblastoma, Gliosarcoma

Start: 2025-04-07End: 2028-04-01Target: 60Updated: 2026-09-09

Related Papers

DDDR-57. A brain-penetrant EGFR inhibitor overcomes EGFR variant heterogeneity in glioblastoma

Neuro-Oncology2025-11-01

A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma

Neuro-Oncology Advances2025-01-011 citations